睿知中国医院研究地图
候选清单

正在招募肺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

ClinicalTrials.gov 上登记的一项肺癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07744529,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Negative serum pregnancy test, and effective contraception from signing the informed consent form until 6 months after the last chemotherapy dose.

    入选标准第 11 条

  3. Complete blood count: absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3), platelets >=75 x 10\^9/L, hemoglobin >=9 g/dL (if bone marrow is involved, platelets >=50 x 10\^9/L, ANC >=1.0 x 10\^9/L and hemoglobin >=8 g/dL).

    入选标准第 6 条

    Liver function: serum bilirubin <=1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 x ULN (if there is liver involvement, AST and ALT <=5 x ULN are allowed).

    入选标准第 7 条

    Renal function: serum creatinine <=1.5 x ULN.

    入选标准第 8 条

    Coagulation function: INR <=1.5 x ULN; PT and APTT <=1.5 x ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range of anticoagulant treatment at screening).

    入选标准第 9 条

  4. History of other malignancies within the past 5 years.

    排除标准第 2 条

    Patients with known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome.

    排除标准第 4 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07744529,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation in the clinical study: fully understands and is informed of this study and signs the written informed consent form; is willing and able to complete all trial procedures.
  2. Age: >=18 years; male or female.
  3. Patients with EGFR-mutated lung adenocarcinoma with leptomeningeal metastasis diagnosed according to the EANO-ESMO guidelines.
  4. Expected survival of at least 3 months.
  5. Adequate organ and bone marrow function, with no severe hematopoietic abnormality and no severe cardiac, pulmonary, hepatic or renal dysfunction or immunodeficiency (within 14 days before use of study drug, no blood transfusion, granulocyte colony-stimulating factor or other relevant medical support):
  6. Complete blood count: absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3), platelets >=75 x 10\^9/L, hemoglobin >=9 g/dL (if bone marrow is involved, platelets >=50 x 10\^9/L, ANC >=1.0 x 10\^9/L and hemoglobin >=8 g/dL).
  7. Liver function: serum bilirubin <=1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 x ULN (if there is liver involvement, AST and ALT <=5 x ULN are allowed).
  8. Renal function: serum creatinine <=1.5 x ULN.
  9. Coagulation function: INR <=1.5 x ULN; PT and APTT <=1.5 x ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range of anticoagulant treatment at screening).
  10. Left ventricular ejection fraction (LVEF) in cardiac function examination >=50%.
  11. Negative serum pregnancy test, and effective contraception from signing the informed consent form until 6 months after the last chemotherapy dose.
  12. Thyroid-stimulating hormone (TSH), free thyroxine (FT4) or free triiodothyronine (FT3) within +/-10% of the normal range.
  13. Ophthalmic examination, including dilated fundus examination, slit-lamp examination and color fundus photography.

排除标准:Exclusion Criteria:

  1. Currently participating in another clinical study, or less than 4 weeks between the first dose of the study drug and the end of treatment in a previous clinical study.
  2. History of other malignancies within the past 5 years.
  3. Patients who have received CNS-directed prophylactic treatment.
  4. Patients with known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome.
  5. Patients with active autoimmune disease or a history of autoimmune disease with a high risk of recurrence, including but not limited to immune-related neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue disease, scleroderma, inflammatory bowel cancer (including Crohn disease and ulcerative colitis), autoimmune hepatitis, toxic epidermal necrolysis or Stevens-Johnson syndrome.
  6. Patients with active chronic hepatitis B or active hepatitis C. Patients who are positive for hepatitis B surface antigen or hepatitis C virus antibody during screening may be enrolled only after further HBV DNA titer testing (not higher than 1000 IU/mL) and HCV RNA testing (not exceeding the lower limit of detection of the assay), and after active hepatitis B or hepatitis C infection requiring treatment has been excluded. Hepatitis B virus carriers, patients with stable hepatitis B after drug treatment and patients with cured hepatitis C may be enrolled.
  7. Active pulmonary tuberculosis.
  8. Current interstitial lung disease or infectious pneumonia.
  9. Active infection requiring systemic anti-infective therapy, including but not limited to bacterial, fungal or viral infection.
  10. Within 6 months before screening, New York Heart Association (NYHA) class III or IV heart failure, unstable angina, severe poorly controlled ventricular arrhythmia, or electrocardiographic evidence of acute ischemia or myocardial infarction.
  11. QTcF interval >480 msec, unless secondary to bundle branch block.
  12. Uncontrolled comorbid disease, including but not limited to uncontrolled hypertension, active peptic ulcer or bleeding disorder.
  13. History of psychiatric illness; incapacity or limited capacity for civil conduct.
  14. In the judgment of the investigator, the patient's underlying condition may increase the risk of receiving study drug treatment or confound the occurrence and assessment of toxic reactions.
  15. Other patients whom the investigator considers unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07744529, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07744529,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07744529